Mattia Cocco

Mattia Cocco

Auto-generated profile, based on publicly available information

Mattia Cocco

Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 March 2016 in ChemMedChem
Verified
Journal Article
Closed access
PDF file
MCMattia Cocco
Mattia Cocco
GMGianluca Miglio
Gianluca Miglio
MGMarta Giorgis
Marta Giorgis
DGDavide Garella
Davide Garella
EMElisabetta Marini
Elisabetta Marini
Massimo BertinariaMassimo Bertinaria
Massimo Bertinaria

1 August 2025 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
SDSusan H. Davis
Susan H. Davis
MMMichael Mathieson
Michael Mathieson
KBKirsteen I. Buchanan
Kirsteen I. Buchanan
ADAlice Dawson
Alice Dawson
ASAlasdair Smith
Alasdair Smith
LCLaura A. T. Cleghorn
Laura A. T. Cleghorn
There is currently a public health crisis due to the rise of multidrug-resistant tuberculosis cases, as well as the rise in the number of deaths from tuberculosis. To achieve the United Nations Sustainable Development Goal of ending the tuberculosis epidemic by 2030, new treatments are urgently required. We previously reported the discovery of 49, a preclinical candidate that acted through inhibition of the Mycobacterium tuberculosis lysyl tRNA synthetase (LysRS). In this report, the full medicinal chemistry program is reviewed from the original hit through to the optimized lead. The work was guided by the first crystal structures of M. tuberculosis LysRS. The physicochemical and pharmacokinetic properties were optimized to afford compounds suitable for evaluation in mouse efficacy models of tuberculosis and with the potential for clinical development.

13 May 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
SDSusan H. Davis
Susan H. Davis
MMMichael Mathieson
Michael Mathieson
KBKirsteen I. Buchanan
Kirsteen I. Buchanan
ADAlice Dawson
Alice Dawson
ASAlasdair Smith
Alasdair Smith
LCLaura A.T. Cleghorn
Laura A.T. Cleghorn
There is currently a public health crisis due to the rise of multi-drug-resistant tuberculosis cases, as well as the rise in number of deaths from tuberculosis. To achieve the United Nations Sustainable Development Goal of ending the tuberculosis epidemic by 2030, new treatments are urgently required. We previously reported the discovery of 49 , a pre-clinical candidate that acted through inhibition of the Mycobacterium tuberculosis lysyl-tRNA synthetase (LysRS). In this report, the full medicinal chemistry program is reviewed from the original hit through to the optimised lead. The work was guided by the first crystal structure of M. tuberculosis LysRS. The physicochemical and pharmacokinetic properties were optimised to afford compounds suitable for evaluation in mouse efficacy models of tuberculosis and with the potential for clinical development.